Pelargonium: The Definitive Guide

What is Pelargonium?

Pelargonium sidoides is a South African geranium whose root is used in oral herbal medicines for coughs and acute respiratory infections. EPs 7630 is a proprietary ethanol-derived root extract sold in liquid, syrup and tablet forms. Evidence for that extract cannot automatically be assigned to another species, plant part, tincture or “geranium” product.

Human trials mainly assess symptom scores in acute bronchitis or the common cold. They do not establish prevention, viral clearance, treatment of pneumonia or replacement of antibiotics when bacterial treatment is indicated. NCCIH describes possible symptom relief but rates the evidence as low quality. [1]

Typical Pelargonium Protocols

There is no RDA, AI or tolerable upper intake level. Drops and milligrams cannot be converted without product-specific data.

Titration

No self-titration schedule applies across products.

Timing

Protocols divided administrations around meals.

Durée

Studies were short; long-term safety is not established.

Stopping

Stop and seek review for allergy or hepatic symptoms.

What is Pelargonium commonly used for?

People use Pelargonium for acute cough, bronchitis, colds and sinus symptoms. The outcome in most trials is symptom reduction over several days, not elimination of a pathogen or prevention of complications. A feasibility study cannot answer efficacy even when exploratory symptom numbers appear favorable. [2]

The evidence base is unusually concentrated on one commercial extract. That improves formulation consistency inside the research but limits generalization and makes manufacturer relationships important to disclose. [3]

Which form and label details matter?

Record species, root as the plant part, extraction solvent and ratio, liquid versus tablet, extract amount per administration, frequency, alcohol content and co-ingredients. In Willcox 2021, liquid and tablets delivered the same named extract but used different units. Thirty drops were about 1.5 mL; a tablet contained 20 mg. [2]

Do not convert drops to milligrams from another label. Drop size, extract concentration and drug-extract ratio vary. Products described as P. reniforme, mixed Pelargonium species or homeopathic dilutions are not the studied EPs 7630 regimen.

What does the human evidence show?

Willcox 2021 recruited 134 UK primary-care adults with acute cough and lower-respiratory symptoms. Practices were assigned a liquid or tablet presentation, then participants received Kaloba or matched placebo. The study’s purpose was to test recruitment, adherence and diary methods for a larger trial. It allowed no antibiotic, immediate antibiotic or delayed prescription according to clinical practice. It was not powered for a definitive efficacy conclusion. [2]

Kamin 2010 randomized 400 participants age 6–18 with acute bronchitis to placebo or 30, 60 or 90 mg/day of EPs 7630 for seven days. The actual administrations were 10, 20 or 30 mg three times daily. Bronchitis Severity Score improved more with 60 and 90 mg/day than placebo, without a relevant difference between those two doses. This is a research schedule, not a universal pediatric dose. [4]

Kardos 2022 pooled 11 placebo-controlled trials and 2,195 participants. Cough response and remission estimates favored EPs 7630 in adult and pediatric acute bronchitis and adult common cold. All trials concerned the same proprietary extract; three meta-analysis authors were manufacturer employees and several authors reported manufacturer relationships. Those facts do not erase results, but they increase the value of independent replication. [3]

How might Pelargonium work?

Root prodelphinidins and coumarin-related constituents have been studied for effects on microbial adhesion, ciliary activity, inflammatory signaling and host responses. Laboratory activity does not show clinical pathogen clearance. Symptom trials provide the more direct evidence for the intended use.

What are the risks and interactions?

Common reported effects include gastrointestinal upset, rash and hypersensitivity. Rare liver injury reports have prompted warnings, although causality in individual reports is disputed and alternative causes were often incompletely excluded. Stop and seek review for yellow skin or eyes, dark urine, pale stools, severe upper-abdominal pain or unusual fatigue. [5]

Avoid after a previous reaction to Pelargonium. Review use with anticoagulants, antiplatelet medicines, liver disease or complex medication regimens; interaction magnitudes are not well quantified. Liquid products may contain ethanol. Pregnancy and breastfeeding evidence is inadequate, and pediatric use should follow an age-specific licensed product and clinician or pharmacist advice.

Seek urgent care for breathing difficulty, facial or throat swelling, fainting, coughing blood, blue lips, confusion, severe dehydration, chest pain or signs of pneumonia.

Legal status in the United States and Canada

In the United States, products may be sold as dietary supplements without preapproval as bronchitis treatments. In Canada, a licensed natural health product carries an NPN tied to its formulation and conditions of use.

What should be monitored?

Record the exact product, lot, dosage form, drops or milligrams per administration, number of daily administrations, relationship to meals, symptom onset, temperature, cough score, breathing, antibiotic plan, alcohol exposure from the product, rash and gastrointestinal or hepatic symptoms.

What happens after stopping?

No withdrawal syndrome or taper is established. Cough may persist after stopping and warrants reassessment if it worsens.

How should Pelargonium be stored?

Follow the label, keep it sealed and away from children, and retain lot and expiry details.

Community experience

Community reports often mix Kaloba, Umckaloabo, syrups, tablets and generic tinctures. They can reveal taste, adherence and tolerability problems but cannot establish efficacy or product equivalence.

How does Pelargonium compare with other approaches?

Pelargonium does not replace diagnostic assessment, hydration, vaccination or indicated antimicrobial treatment. Andrographis, echinacea and elderberry use different preparations and endpoints; their doses are not convertible.

Common questions

Did the UK trial prove efficacy?

No. It primarily assessed feasibility and was not powered to do so. [2]

What was the exact adult dose?

30 drops, about 1.5 mL, or a 20 mg tablet three times daily, 30 minutes before meals. [2]

Are generic products equivalent?

That is not established; most evidence concerns EPs 7630.

Why disclose manufacturer ties?

They help readers judge the need for independent replication. [3]

Can it replace an antibiotic?

No. Diagnosis and clinical indications determine treatment.

What about the liver?

Causality of rare reports is uncertain, but hepatic symptoms require stopping and assessment. [5]

Is long-term use established?

No. The featured protocols are short.

Glossary

Terms used in this guide.

EPs 7630

The proprietary root extract studied in the cited trials.

Bronchitis Severity Score

A five-symptom score used in bronchitis trials.

Feasibility

Whether a larger study can be run; not proof of efficacy.

Extract ratio

Relationship between starting plant material and resulting extract.

Titration

Planned dose adjustment; no shared schedule is established here.

How this guide was researched

Priority went to NCCIH guidance, a full independent feasibility trial, the 2022 meta-analysis, a full pediatric trial and EMA material. Evidence was refreshed October 9, 2026.

How this guide was made

The ledger preserves extract, amount per administration, frequency, meals, duration, antibiotic strategy, study purpose and financial relationships.

Sources

Related guides